



Global Research Collaboration for Infectious Disease Preparedness

GloPID-R

A multi-funder initiative
across the continents

Time-series in research

Research Preparedness




Research Response



Funding begins



Funding ends



Why GloPID-R ?

- Research Response to emerging infectious threats requires a rapid international research response;
- There is currently no forum for the coordination of an international research response to such outbreaks;
- Joint work in 'peacetime' will prepare the ground for successful collaboration in the case of an outbreak

What is GloPID-R ?

- A network of research funders - launched in Brussels in February 2013;
- GloPID-R members are funders from EU, France, Spain, U.S., Canada, South Africa, Brazil, Korea, Thailand, Australia;
- Governance 'GloPID-R Charter' adopted 30 September 2014 in Montreal, Canada;
 - Interim chair from the European Commission, interim vice chairs from Brazil, Canada, France and South Africa;

GloPID-R's is not

- *a consortium to coordinate a public health response***
- a new funding organisation**
- GloPID-R aims to make the work of its members more effective through collaboration and by jointly addressing the barriers to research;

Objectives OF GloPID-R ?

GloPID-R aims to facilitate a global research response by:

- Facilitating exchange of information between funders;
- Connecting the existing and future research networks in this area;
- Addressing scientific, logistical, legal, regulatory, ethical and financial challenges;
- Establishing a strategic agenda to address these challenges;
- Establishing collaboration with public health and veterinary services, industry, regulatory agencies and patient groups

Ongoing activities/next steps

- **Ebola Virus disease research:**
 - regular exchange of information on research priorities
 - funders' meeting on 11 December 2014;
- **Development of the Strategic agenda:** first round of discussions in Montreal September 2014;
- **GloPID-R secretariat** (Fondation Mérieux & Oxford University), selected and funded from the first Horizon 2020 call. Operational as of 1 January 2015;
- **Next GloPID-R meeting** planned for May 2015 in South Africa. Post Ebola research will be the main point on the agenda

**Funding organisations from other
countries invited to join.**

Projects funded by the EC

Title	Coordination	Budget
<p align="center">EbolaVac</p> <p>Development of a Chimpanzee Adenovirus Type 3 Ebolavirus Zaire Vaccine</p>	<p align="center">GSK</p>	<p align="center">15,153,216</p>
<p align="center">REACTION</p> <p>Evaluation of the efficacy and of the antiviral activity of T-705 (favipiravir) during Ebola virus infection in non-human primates humans</p>	<p>Inserm: Hervé Raoul, BSL4 lab in Lyon</p>	<p align="center">2,575,810</p>
<p align="center">Ebola_Tx</p> <p>Emergency evaluation of convalescent blood and plasma for Ebola Viral Disease (EVD) in affected West African countries.</p>	<p>Institut de Médecine Tropicale: Johan van Griensven</p>	<p align="center">2,892,171</p>
<p align="center">EVIDENT</p> <p>Ebola Virus Disease - correlates of protection, determinants of outcome, and clinical management</p>	<p align="center">Bernhard-nocht-institut fuer tropenmedizin : Stephen Gunther</p>	<p align="center">1,759,326</p>
<p align="center">IF-EBOLA</p> <p>Control of the Ebola Oubreak by both innovative Ultrasensitive Detection of EBOV and therapy I</p>	<p align="center">IRD: Francisco Veas</p>	<p align="center">1,992,770</p>